IRWD Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A

$IRWD I must be the single greatest moron to ever invest in Ironwood. Five years of complete disappointment and frustration, yet here I am, still holding and adding more. Yes, I added another 10K shares today at $4.09.

$IRWD Slowly but surely moving higher high. Stay focused and don’t let the bashers lunatics distract you.

$IRWD everytime the market learns they are going to open their mouth in a ER or conference the stock tanks. Quiet period was much better

$IRWD So glad I averaged down in $4.50 range for $EBS. Should have dumped the giant turd known as Ironwood and rolled that as well. Oh Well. #Saveironwood #tommccourtmustgo

$IRWD Just my opinion but I find it remarkable that not a single member of Ironwood's leadership has faced accountability for five years of underperformance — no departures, no clawbacks, no recalibration of pay to reflect results. Compensation committees typically defend pay-for-performance alignment as a bedrock fiduciary principle; here, the correlation between realized shareholder value and executive retention appears effectively absent. Eighteen board meetings in 2025 versus seven in 2024 suggests a board reacting to mounting pressure, not one exercising proactive oversight. This is what governance failure looks like when a board conflates activity with accountability.

$IRWD catalyst map from here: Scheduled: -AbbVie Q3/Linzess readout—mid/late Oct. -Ironwood Q3—late Oct. Unscheduled: -STARS-2 enrollment/regulatory update -New STARS Extend data -FDA clarification The big TBD: -STARS-2 efficacy readout The really, really big TBD -Somebody buys the damn company. That’s basically my thesis right now: LINZESS can keep improving the floor. Apraglutide changes the ceiling. A buyout changes the conversation entirely. If you’ve got a better catalyst map, post it. If not, I assume the #hashtags resume shortly… 👻

$IRWD bought a position here again i like the chart and outlook: Looks like a bullish upside move could happen in the near time Summary Surging Profitability: In Q2 2026, the company doubled its net income to $51.3 million and significantly increased revenue, driven by highly profitable LINZESS sales. Clean Balance Sheet: Ironwood recently paid off a $200 million debt note entirely with cash on hand, avoiding any shareholder dilution. Deep Value: At a market cap of roughly $710 million, the stock is currently priced lower than the total cash LINZESS is expected to generate before its patent expires in 2029. Pipeline Upside: The actively enrolling Phase 3 STARS-2 trial for apraglutide offers massive, long-term growth potential if the data is positive. They hired a new CMO this month for that. Buyout Target: The combination of a massive, guaranteed cash cow (LINZESS), a clean balance sheet, and a suppressed valuation makes it an incredibly attractive acquisition target for AbbVie.

$IRWD i will buy 50% more shares on Dec 26th, 1016 and sell this on the next good news ( sometime in 2027). When it spikes to $8-10. These guys can’t do anything right. Incompetent and lazy management.

$IRWD will this dip to $3.86? $3.70? it's just going to make zig zags for the next few months..... trying to figure out the lower band.

$IRWD While I'm expecting this to go down, the structure also shows it could go up with the very long but unusual bull flag. It's a bit of a coinflip.

$IRWD October is getting interesting. 👀 ACG—Oct. 9–14. Watching for any new apraglutide/STARS data. 👀 $ABBV Q3—Linzess sales performance And you never know when an October surprise may drop…

$IRWD Does anyone know when is company expected to release final out come of Ph-3 trial result ?

$IRWD apraglutide works right? Like there’s no way it’s gonna be inferior to GATTEX? Or a safety concern? Because if these guys blow it and they spent 1.1 bill on apraglutide they’re idiots.